1. A 58-year-old man with Child-Pugh class C cirrhosis requires treatment with metronidazole for a complicated intra-abdominal infection. His renal function is normal (creatinine clearance 85 mL/min). Which of the following best describes the pharmacokinetic adjustment required and the rationale for it?
A) No dose adjustment is needed because metronidazole is eliminated entirely by renal glomerular filtration, and his normal creatinine clearance ensures adequate drug excretion without toxic accumulation.
B) The dose should be reduced because metronidazole undergoes extensive renal tubular secretion that is impaired by the hepatorenal syndrome that invariably accompanies Child-Pugh class C cirrhosis, creating dual elimination failure.
C) Dose reduction is warranted because metronidazole is eliminated primarily by hepatic oxidation and glucuronide conjugation; severe hepatic impairment prolongs the half-life beyond its normal range of approximately 6 to 10 hours, increasing the risk of accumulation and neurotoxicity — no adjustment is required for normal renal function.
D) Dose reduction is not required for hepatic impairment because metronidazole bypasses hepatic first-pass metabolism entirely via direct intestinal absorption into the systemic circulation, making its clearance independent of hepatic function.
E) The dose interval should be extended from every 8 hours to every 24 hours because metronidazole is eliminated by a combination of renal and biliary routes equally, and hepatic impairment reduces only the biliary component, requiring a partial compensatory adjustment.
ANSWER: C
Rationale:
Metronidazole is eliminated primarily through hepatic metabolism — oxidation and glucuronide conjugation — with approximately 60 to 80 percent of drug appearing in urine as inactive metabolites. The half-life under normal conditions is approximately 6 to 10 hours, supporting twice-daily or three-times-daily dosing regimens. In severe hepatic impairment such as Child-Pugh class C cirrhosis, the metabolic capacity for these hepatic pathways is substantially reduced, prolonging the half-life and increasing the risk of drug and metabolite accumulation. Neurological toxicities — including peripheral neuropathy and encephalopathy — are dose- and exposure-dependent, making accumulation clinically significant. Renal impairment alone does not require metronidazole dose adjustment because the drug itself is cleared hepatically; only the inactive metabolites are renally excreted, and their accumulation does not produce toxicity. This patient's normal creatinine clearance is therefore irrelevant to the dosing decision; the hepatic impairment is the sole pharmacokinetic driver requiring adjustment.
Option A: Option A is incorrect because metronidazole is not eliminated by renal glomerular filtration; the parent drug undergoes hepatic metabolism, and renal excretion of inactive metabolites is not rate-limiting for drug clearance or toxicity.
Option B: Option B is incorrect because hepatorenal syndrome is not the mechanism of concern and does not invariably accompany cirrhosis; the dose reduction is warranted because of direct hepatic metabolic impairment, not secondary renal dysfunction.
Option D: Option D is incorrect because while metronidazole does have high oral bioavailability, this reflects the absence of significant first-pass extraction rather than bypass of hepatic metabolism; systemic clearance after absorption still depends on hepatic oxidative metabolism, which is impaired in cirrhosis.
Option E: Option E is incorrect because metronidazole is not eliminated equally by renal and biliary routes; it is a predominantly hepatically metabolized drug, and the framing of a partial biliary adjustment misrepresents the pharmacokinetics.
2. A 66-year-old man with atrial fibrillation maintained on warfarin (INR target 2.0–3.0) is prescribed a seven-day course of metronidazole for bacterial vaginosis in his partner — he asks whether he also needs treatment. Incidentally, his INR is checked three days after starting his own course of metronidazole for a separate intra-abdominal indication and is found to be 4.8. Which cytochrome P450 isoform does metronidazole inhibit, and why does this produce clinically significant anticoagulant potentiation?
A) Metronidazole inhibits CYP2C9, the isoform responsible for metabolizing the S-enantiomer of warfarin, which is approximately three to five times more potent as a vitamin K epoxide reductase inhibitor than the R-enantiomer; inhibition of S-warfarin clearance directly amplifies anticoagulant effect and raises INR.
B) Metronidazole inhibits CYP3A4, the predominant isoform responsible for metabolizing both enantiomers of warfarin equally; pan-enantiomer inhibition doubles the effective warfarin plasma concentration and produces a proportional doubling of the INR.
C) Metronidazole inhibits CYP2E1, the isoform that activates warfarin's prodrug form; inhibition prevents prodrug activation and paradoxically reduces the anticoagulant effect, meaning the elevated INR in this patient is most likely explained by a dietary vitamin K change rather than a drug interaction.
D) Metronidazole inhibits CYP1A2, the isoform responsible for R-warfarin metabolism; because R-warfarin is the more potent enantiomer, CYP1A2 inhibition raises the active drug fraction disproportionately and produces the observed supratherapeutic INR.
E) Metronidazole does not inhibit any cytochrome P450 isoform directly; it potentiates warfarin by displacing it from plasma albumin binding sites, increasing the free fraction available for pharmacological action and causing the INR elevation observed in this patient.
ANSWER: A
Rationale:
Metronidazole is a clinically important inhibitor of CYP2C9, the cytochrome P450 isoform that is the primary metabolic pathway for the S-enantiomer of warfarin. Warfarin is administered as a racemic mixture of R- and S-enantiomers. The S-enantiomer is approximately three to five times more pharmacologically potent as an inhibitor of vitamin K epoxide reductase (VKOR) than the R-enantiomer, meaning it contributes disproportionately to the anticoagulant effect. When CYP2C9 is inhibited by metronidazole, S-warfarin plasma concentrations rise because its hepatic clearance is reduced, producing a clinically significant amplification of anticoagulant effect and INR elevation. This interaction is well-documented and requires close INR monitoring — typically within one week of initiation — with warfarin dose reduction frequently necessary.
Option B: Option B is incorrect because metronidazole does not inhibit CYP3A4; CYP3A4 is involved in R-warfarin metabolism, not S-warfarin; and the mechanism described — equal inhibition of both enantiomers — is not how the metronidazole-warfarin interaction works.
Option C: Option C is incorrect because metronidazole does not inhibit CYP2E1; CYP2E1 is relevant to acetaminophen metabolism and alcohol metabolism, not warfarin; warfarin is not a prodrug requiring activation, and the interaction described is fabricated.
Option D: Option D is incorrect because the more pharmacologically potent enantiomer is S-warfarin, not R-warfarin; CYP1A2 is involved in R-warfarin metabolism, and CYP1A2 inhibition is not the mechanism of the metronidazole-warfarin interaction.
Option E: Option E is incorrect because metronidazole's potentiation of warfarin is mediated by CYP2C9 inhibition affecting S-warfarin metabolism, not by protein displacement; protein displacement interactions rarely produce sustained clinically significant INR changes because free drug is rapidly redistributed and cleared.
3. A 71-year-old woman with Crohn's disease has been receiving metronidazole 500 mg three times daily for eight weeks for a perianal fistula. She develops progressive confusion, dysarthria, and gait ataxia. A brain MRI is obtained. Which of the following MRI findings would be most characteristic of metronidazole-induced central nervous system (CNS) toxicity, and what is the expected course if the drug is discontinued promptly?
A) Asymmetric cortical signal abnormalities on diffusion-weighted imaging (DWI) in the frontoparietal cortex bilaterally, consistent with toxic leukoencephalopathy; the lesions are typically irreversible even with drug discontinuation due to permanent myelin destruction.
B) Symmetric T1 hyperintensities in the basal ganglia (caudate and putamen) bilaterally, consistent with manganese deposition from metronidazole-mediated disruption of hepatic manganese excretion; improvement occurs over six to twelve months after drug cessation.
C) Symmetric T2 hyperintensities throughout the periventricular white matter, indistinguishable from demyelinating disease such as multiple sclerosis; the distribution is non-specific for metronidazole toxicity and requires lumbar puncture to exclude infectious encephalitis.
D) Unilateral T2 signal abnormality in the thalamus and ipsilateral posterior limb of the internal capsule, consistent with small vessel ischemic disease precipitated by metronidazole-induced hyperviscosity from polycythemia; this finding is irreversible.
E) Symmetric T2 hyperintensities in the dentate nuclei of the cerebellum and the dorsal brainstem, a pattern that is characteristic of metronidazole-induced encephalopathy; the lesions are typically reversible if metronidazole is promptly discontinued.
ANSWER: E
Rationale:
Metronidazole-induced CNS toxicity produces a characteristic and diagnostically recognizable MRI pattern: symmetric T2 (T2-weighted sequence)-hyperintense signal abnormalities in the dentate nuclei of the cerebellum and the dorsal brainstem, often also involving the splenium of the corpus callosum and midbrain. This pattern reflects the selective vulnerability of these structures to metronidazole's mitochondrial toxic effects. Clinically, patients present with cerebellar dysfunction — ataxia, dysarthria, nystagmus — and encephalopathy, which is exactly the presentation described. Crucially, if metronidazole is promptly discontinued upon recognition of this syndrome, the MRI abnormalities and clinical symptoms are typically reversible. This reversibility distinguishes metronidazole encephalopathy from other toxic or structural causes of cerebellar dysfunction and is an important point: delaying recognition and continuation of the drug risks permanent injury. Prolonged courses (typically exceeding four weeks at standard doses) and high cumulative exposures increase risk.
Option A: Option A is incorrect because metronidazole toxicity does not characteristically produce asymmetric cortical DWI signal changes in the frontoparietal cortex; that pattern would suggest stroke or prion disease, not metronidazole toxicity, and the lesions of metronidazole encephalopathy are reversible, not irreversible.
Option B: Option B is incorrect because symmetric T1 basal ganglia hyperintensities suggest manganese or calcium deposition, not metronidazole toxicity; this finding is associated with hepatic encephalopathy from cirrhosis causing impaired manganese clearance, not with metronidazole.
Option C: Option C is incorrect because periventricular white matter T2 lesions are associated with demyelinating disease such as multiple sclerosis, not with metronidazole toxicity; the characteristic metronidazole pattern involves deep cerebellar (dentate nucleus) and brainstem structures, not periventricular white matter.
Option D: Option D is incorrect because unilateral thalamic and internal capsule signal changes are consistent with small vessel ischemic disease or thalamic stroke, not metronidazole encephalopathy; metronidazole toxicity produces symmetric cerebellar and brainstem changes, and polycythemia-induced hyperviscosity is not a metronidazole adverse effect.
4. A microbiologist presents data showing that a clinical isolate of Trichomonas vaginalis is resistant to metronidazole in vitro despite the drug's intact nitro functional group and the organism's anaerobic metabolism. Which of the following best describes the molecular mechanism most likely responsible for acquired metronidazole resistance in anaerobic organisms?
A) The resistant isolate produces a plasmid-encoded nitroimidazole acetyltransferase that acetylates the nitro group of metronidazole before reduction can occur, converting the drug to a stable non-toxic acetylated derivative that cannot be further activated.
B) Resistance is most commonly mediated by reduced expression or mutation of the low-redox-potential electron transport proteins — particularly ferredoxin and pyruvate-ferredoxin oxidoreductase (PFOR) — that are responsible for reductive activation of metronidazole, or by upregulation of DNA repair mechanisms that counteract drug-induced strand breaks.
C) The resistant isolate overexpresses a broad-spectrum efflux pump of the major facilitator superfamily (MFS) that actively exports metronidazole before intracellular reduction occurs, maintaining intracellular drug concentrations below the threshold required for DNA damage.
D) Resistance arises from a point mutation in the bacterial DNA gyrase subunit A gene (gyrA) that reduces metronidazole's affinity for its DNA binding site, preventing the reactive intermediates from intercalating between DNA base pairs even when the drug is fully reduced.
E) The resistant isolate carries a chromosomal mutation in the gene encoding dihydrofolate reductase (DHFR) that prevents metronidazole's reactive intermediates from inhibiting folate synthesis, preserving thymidine production and allowing DNA replication to continue despite ongoing drug exposure.
ANSWER: B
Rationale:
Metronidazole requires reductive activation by low-redox-potential electron transport proteins — principally ferredoxin and pyruvate-ferredoxin oxidoreductase (PFOR) — to generate the cytotoxic nitro radical intermediates that cause DNA strand breaks. The primary resistance mechanisms in anaerobic bacteria and in organisms such as Trichomonas vaginalis and Helicobacter pylori involve either reduced expression of these activating proteins (which decreases the rate of drug activation, producing lower concentrations of toxic intermediates) or outright mutation or deletion of the genes encoding ferredoxin or PFOR. A secondary resistance pathway involves upregulation of DNA repair enzymes that can correct the strand breaks caused by whatever reactive intermediates are produced, effectively counteracting the drug's lethal mechanism. In H. pylori, resistance rates exceeding 20 to 40 percent in many populations reflect these mechanisms and have important clinical implications for the selection of eradication regimens.
Option A: Option A is incorrect because a nitroimidazole acetyltransferase resistance mechanism of the type described for aminoglycosides or chloramphenicol does not exist as a characterized clinical resistance mechanism for metronidazole; this mechanism is fabricated.
Option C: Option C is incorrect because while efflux pumps are important resistance mechanisms for many antibiotics, they have not been established as the primary mechanism of clinically relevant metronidazole resistance in anaerobic organisms; the dominant mechanism is failure of reductive activation.
Option D: Option D is incorrect because metronidazole does not inhibit DNA gyrase; that is the mechanism of fluoroquinolones; metronidazole's cytotoxic intermediates cause direct DNA strand breaks through non-enzymatic alkylation, and gyrA mutations are not relevant to metronidazole resistance.
Option E: Option E is incorrect because metronidazole does not act through dihydrofolate reductase inhibition; DHFR is the target of trimethoprim; metronidazole's mechanism is entirely distinct, involving direct DNA damage by reactive nitro intermediates, not folate pathway inhibition.
5. A 29-year-old woman presents with vaginal discharge, an elevated vaginal pH, and a positive whiff test. Microscopy shows clue cells. The diagnosis is bacterial vaginosis (BV). She has no drug allergies and is not pregnant. Which of the following most accurately describes the guideline-recommended pharmacological treatment options for this patient?
A) Oral clindamycin 300 mg twice daily for seven days is the preferred first-line regimen for BV because it provides superior bactericidal activity against Gardnerella vaginalis and the associated anaerobic flora compared to metronidazole, which is only bacteriostatic.
B) A single oral dose of metronidazole 2 g is the preferred regimen for BV because single-dose therapy maximizes adherence, achieves higher peak plasma concentrations than divided dosing, and produces equivalent microbiological cure rates to multi-day regimens in all patient populations.
C) Topical clindamycin 2% cream applied intravaginally for seven nights is the only appropriate treatment option for a non-pregnant woman with BV because systemic metronidazole is contraindicated in reproductive-age women due to potential teratogenicity.
D) Guideline-recommended first-line options for BV include oral metronidazole 500 mg twice daily for seven days or metronidazole 0.75 percent intravaginal gel once daily for five days; oral clindamycin 300 mg twice daily for seven days and intravaginal clindamycin cream are also guideline-supported alternatives.
E) Fosfomycin 3 g as a single oral dose is now considered a first-line treatment for BV because it achieves high vaginal mucosal concentrations, has activity against the anaerobic organisms causing BV, and eliminates the need for multi-day treatment courses associated with poor adherence.
ANSWER: D
Rationale:
Current CDC guidelines for bacterial vaginosis recommend multiple equivalent first-line options. Oral metronidazole 500 mg twice daily for seven days is the most widely used regimen and achieves cure rates of approximately 70 to 80 percent. Metronidazole 0.75 percent intravaginal gel applied once daily for five days is an equally guideline-supported topical alternative that achieves equivalent cure rates with lower systemic exposure and reduced risk of the disulfiram-like reaction if the patient consumes alcohol. Oral clindamycin 300 mg twice daily for seven days and intravaginal clindamycin 2 percent cream applied nightly for seven days are also listed as recommended alternatives, providing treatment options for patients with metronidazole intolerance or allergy. The clinical relevance of knowing these options is in tailoring therapy to individual patient circumstances — the woman who cannot avoid alcohol, the woman who prefers topical therapy, or the woman who has failed prior metronidazole courses.
Option A: Option A is incorrect because oral clindamycin is a guideline-supported alternative, not the preferred first-line agent over metronidazole; the claim of superior bactericidal activity over the bacteriostatic metronidazole is not the basis for clinical guidelines, and both achieve similar cure rates in clinical trials.
Option B: Option B is incorrect because the single 2 g oral metronidazole dose is not the preferred regimen for BV; while single-dose therapy is used for trichomoniasis, the multi-day 500 mg BID regimen is standard for BV because single-dose regimens have lower cure rates for BV specifically.
Option C: Option C is incorrect because metronidazole is not contraindicated in reproductive-age non-pregnant women; metronidazole is safe in this population, and topical therapy is one option among several, not the only appropriate treatment.
Option E: Option E is incorrect because fosfomycin is not a guideline-recommended treatment for bacterial vaginosis; its clinical utility is in uncomplicated lower urinary tract infection caused by susceptible uropathogens, and it does not have established efficacy data for BV.
6. A clinical pharmacology fellow reviews the antibacterial activity of clindamycin and asks a junior colleague to describe its bactericidal versus bacteriostatic properties and what clinical implications this distinction carries. Which of the following most accurately characterizes clindamycin's activity?
A) Clindamycin is uniformly bactericidal against all susceptible organisms at all clinical concentrations because ribosomal inhibition necessarily produces irreversible ribosomal damage that prevents any bacterial recovery after drug exposure.
B) Clindamycin is bacteriostatic at all concentrations against Gram-positive organisms but bactericidal against anaerobes; this differential activity reflects the greater metabolic dependence of anaerobic organisms on ongoing protein synthesis, making ribosomal inhibition lethal rather than merely suppressive.
C) Clindamycin is bacteriostatic at most clinical concentrations — inhibiting growth by blocking ribosomal protein synthesis without necessarily killing the organism — though it may be bactericidal at higher concentrations against some susceptible organisms; this is clinically relevant because bacteriostatic activity depends on an intact host immune response to clear surviving organisms.
D) Clindamycin is a concentration-dependent bactericidal agent whose killing is maximized by achieving peak plasma concentrations substantially above the minimum inhibitory concentration (MIC); dosing should therefore use the highest tolerable single daily dose to exploit the concentration-dependent kill kinetics.
E) Clindamycin is bacteriostatic in vitro but achieves bactericidal concentrations exclusively within phagocytes due to its intracellular concentration by macrophages; this intraphagocytic accumulation makes it effectively bactericidal in vivo against organisms that survive inside phagocytes such as Staphylococcus aureus.
ANSWER: C
Rationale:
Clindamycin is classified as a bacteriostatic antibiotic at most clinically achievable concentrations. By inhibiting the 50S ribosomal subunit at the peptidyl transferase center and blocking transpeptidation and translocation, clindamycin arrests bacterial protein synthesis without directly killing the organism. Surviving bacteria resume growth when drug is removed, which is the defining characteristic of bacteriostatic activity. At higher concentrations, clindamycin may achieve bactericidal activity against some susceptible organisms, but this is not the dominant pharmacodynamic property at standard therapeutic doses. The clinical implication of bacteriostatic activity is significant: effective treatment depends on an intact host immune response — particularly phagocytic function — to eliminate organisms that are merely growth-inhibited rather than killed. This is why bacteriostatic antibiotics are relatively less reliable in profoundly immunocompromised patients or in infections where phagocytes cannot access the site, such as certain endovascular infections. Clindamycin's anti-toxin activity (suppressing toxin gene translation at sub-inhibitory concentrations) is a separate mechanism from its bacteriostatic effect and remains useful even at low drug concentrations.
Option A: Option A is incorrect because bacteriostatic antibiotics — including clindamycin — do not produce irreversible ribosomal damage; the drug binds reversibly, and bacteria resume growth upon drug removal; calling clindamycin uniformly bactericidal is pharmacologically inaccurate.
Option B: Option B is incorrect because the distinction between bacteriostatic and bactericidal activity for clindamycin is not organism-class dependent in the simple way described; it is primarily concentration-dependent, and the premise that anaerobes are selectively killed due to metabolic dependence on protein synthesis is not an established pharmacological principle.
Option D: Option D is incorrect because clindamycin is not a concentration-dependent bactericidal agent; concentration-dependent bactericidal kinetics are the hallmark of aminoglycosides and fluoroquinolones; clindamycin exhibits time-dependent pharmacodynamics consistent with its bacteriostatic mechanism, and once-daily high-dose regimens are not the dosing strategy for clindamycin.
Option E: Option E is incorrect because while clindamycin does concentrate within phagocytes, this property does not transform its mechanism from bacteriostatic to bactericidal in a clinically meaningful and universal way; intraphagocytic activity is relevant to its tissue penetration and efficacy in certain deep infections, but the claim that phagocytic concentration is the exclusive route to bactericidal activity is an oversimplification that misrepresents the pharmacology.
7. An intern presents four statements about clindamycin's antibacterial spectrum and asks which one is correct. Which of the following accurately describes a spectrum property of clindamycin?
A) Clindamycin has no clinically useful activity against aerobic Gram-negative bacteria because their outer membrane restricts drug penetration, and it has no activity against enterococci regardless of species; its clinical spectrum is limited to Gram-positive aerobes, anaerobes (Gram-positive and many Gram-negative), and it covers many community-acquired MRSA strains when D-zone negative.
B) Clindamycin has excellent activity against aerobic Gram-negative rods including Escherichia coli and Klebsiella pneumoniae, making it a reliable empiric option for intra-abdominal infections when used as monotherapy without a Gram-negative partner.
C) Clindamycin reliably covers Enterococcus faecalis and Enterococcus faecium at standard clinical concentrations because enterococci express ribosomal binding sites that are more sensitive to lincosamide inhibition than those of Staphylococcus aureus.
D) Clindamycin has reliable activity against Pseudomonas aeruginosa due to the drug's high lipophilicity allowing diffusion through the pseudomonal outer membrane despite the absence of specific porin channels, making it useful in burn wound infections caused by this organism.
E) Clindamycin covers all Clostridium species including Clostridioides difficile with reliable bactericidal activity; this is the basis for its historical use as the primary treatment for C. diff colitis before more effective agents were identified.
ANSWER: A
Rationale:
Clindamycin's spectrum is defined by two absolute gaps that clinicians must know precisely: it has no useful activity against aerobic Gram-negative bacteria — including the Enterobacteriaceae (E. coli, Klebsiella, Proteus), Pseudomonas, Acinetobacter, and Haemophilus — because the Gram-negative outer membrane prevents the drug from reaching the 50S ribosomal target in clinically relevant concentrations. It also has no activity against enterococci. Within its active spectrum, clindamycin covers most aerobic Gram-positive cocci (including MSSA, many CA-MRSA strains when D-zone negative, Streptococcus pyogenes, and viridans streptococci) and a broad range of anaerobes — Gram-positive anaerobes such as Clostridium (excluding C. diff) and Peptostreptococcus, and many Gram-negative anaerobes including Bacteroides fragilis, though resistance rates in B. fragilis are increasing. This knowledge directly informs clinical prescribing: clindamycin must always be combined with a Gram-negative-active agent when Gram-negative coverage is required.
Option B: Option B is incorrect because clindamycin has no clinically meaningful activity against aerobic Gram-negative rods including E. coli and Klebsiella; using it as monotherapy for intra-abdominal infections without a Gram-negative partner would leave the most common causative organisms untreated.
Option C: Option C is incorrect because clindamycin has no activity against enterococci; enterococcal ribosomal binding sites are not more sensitive to lincosamide inhibition, and enterococcal coverage is a consistent gap in clindamycin's spectrum.
Option D: Option D is incorrect because clindamycin has no reliable activity against Pseudomonas aeruginosa; the claim that its lipophilicity enables pseudomonal outer membrane penetration is pharmacologically incorrect — outer membrane resistance in Gram-negatives involves multiple barriers including porin selectivity, lipopolysaccharide, and efflux pumps that collectively exclude clindamycin.
Option E: Option E is incorrect because Clostridioides difficile is intrinsically resistant to clindamycin; clindamycin is listed among the antibiotics most strongly associated with precipitating C. diff infection by disrupting colonization resistance, not with treating it; clindamycin was never used as a treatment for C. diff colitis.
8. A clinical pharmacologist compares the pharmacokinetic profiles of metronidazole and clindamycin during a teaching session. Which of the following statements most accurately contrasts a pharmacokinetic property that differs meaningfully between the two drugs?
A) Metronidazole has high plasma protein binding of approximately 90 percent, whereas clindamycin has low protein binding of approximately 15 percent; this difference explains why clindamycin achieves superior tissue penetration relative to metronidazole in most body compartments.
B) Both metronidazole and clindamycin are eliminated primarily by renal glomerular filtration, but metronidazole requires dose adjustment for renal impairment at creatinine clearance below 50 mL/min whereas clindamycin does not, reflecting differences in molecular size affecting renal handling.
C) Clindamycin has a half-life of approximately 12 to 18 hours, permitting once-daily dosing and supporting excellent outpatient adherence, whereas metronidazole has a shorter half-life of approximately 1 to 2 hours requiring four-times-daily dosing.
D) Metronidazole and clindamycin have identical oral bioavailability of approximately 90 percent; the clinically meaningful difference is that clindamycin is eliminated entirely by biliary excretion without hepatic metabolism, whereas metronidazole undergoes oxidative hepatic metabolism.
E) Clindamycin has plasma protein binding of approximately 93 percent and is eliminated primarily by hepatic CYP3A4-mediated metabolism with biliary excretion, requiring dose adjustment for severe hepatic but not renal impairment; metronidazole has low protein binding of approximately 10 to 20 percent and is also eliminated hepatically, requiring dose adjustment for severe hepatic impairment.
ANSWER: E
Rationale:
Both metronidazole and clindamycin share the characteristic of hepatic elimination requiring dose adjustment for severe hepatic but not renal impairment, but they differ markedly in protein binding. Clindamycin has high plasma protein binding of approximately 93 percent, which reflects strong albumin binding; despite this, it achieves excellent tissue penetration due to its large volume of distribution (Vd approximately 0.6 to 1.2 L/kg) and concentration within phagocytes. Clindamycin undergoes hepatic metabolism via CYP3A4 with biliary excretion, and no dose adjustment is required for renal impairment. Metronidazole, by contrast, has low protein binding of approximately 10 to 20 percent, which contributes to its wide tissue distribution and exceptional CNS penetration (CSF concentrations reaching 43 to 100 percent of plasma). Both drugs require consideration of hepatic impairment because both are hepatically cleared. Knowing this contrast is clinically useful: clindamycin's high protein binding means its free drug concentration is sensitive to conditions affecting albumin (hypoalbuminemia in malnutrition, hepatic disease), whereas metronidazole's low protein binding makes free drug concentrations more predictable.
Option A: Option A is incorrect because it reverses the protein binding values; metronidazole has low protein binding (10 to 20 percent) and clindamycin has high protein binding (approximately 93 percent), not the other way around.
Option B: Option B is incorrect because neither metronidazole nor clindamycin is eliminated primarily by renal glomerular filtration; both undergo hepatic metabolism as the primary elimination pathway; the statement about renal dose adjustment requirements is also incorrect for both.
Option C: Option C is incorrect because clindamycin's half-life is approximately 2 to 3 hours (not 12 to 18 hours) requiring 6 to 8 hourly dosing, and metronidazole's half-life is approximately 6 to 10 hours (not 1 to 2 hours); the values are reversed and incorrect for both drugs.
Option D: Option D is incorrect because while metronidazole has oral bioavailability close to 90 to 100 percent and clindamycin approximately 90 percent (making this partly accurate), clindamycin is not eliminated entirely by biliary excretion without hepatic metabolism; it undergoes significant CYP3A4-mediated hepatic metabolism before biliary excretion.
9. A clinical microbiology report returns for a Staphylococcus aureus wound isolate from a 40-year-old man with an infected diabetic foot ulcer. The susceptibility panel shows: oxacillin — resistant, erythromycin — resistant, clindamycin — susceptible. A second isolate from a separate patient shows: oxacillin — resistant, erythromycin — resistant, clindamycin — resistant. Which of the following best explains the mechanistic and phenotypic difference between these two isolates, and what additional test is required before prescribing clindamycin for the first patient?
A) The first isolate has constitutive MLSB resistance in which erm gene methyltransferase is expressed at low basal levels sufficient to produce clindamycin resistance in vitro but insufficient to produce clinical resistance in vivo; no additional testing is needed because in vivo pharmacokinetics overcome basal methylation. The second isolate has acquired an additional lincosamide nucleotidyltransferase gene conferring absolute clindamycin resistance.
B) The first isolate likely has inducible MLSB resistance — the erm gene is present but suppressed, producing apparent clindamycin susceptibility in vitro because no inducer is present during routine disk diffusion; clindamycin can induce erm expression in vivo, causing treatment failure. The second isolate has constitutive erm expression producing simultaneous high-level resistance to both macrolides and clindamycin. A D-zone test is required for the first isolate before prescribing clindamycin.
C) The first isolate is a macrolide-susceptible strain in which erythromycin resistance is caused by an efflux pump (mef gene) that cannot export clindamycin because its binding site differs structurally from the macrolide export site; clindamycin can be used safely without further testing. The second isolate has constitutive erm expression.
D) Both isolates have constitutive MLSB resistance encoded by the same erm gene; the apparent clindamycin susceptibility of the first isolate is a laboratory artifact of the disk diffusion inoculum being below the critical threshold needed to detect low-level constitutive resistance, and clindamycin is absolutely contraindicated for the first patient without further confirmatory testing by broth microdilution.
E) The first isolate has acquired a mutation in the clindamycin ribosomal binding site that paradoxically increases drug affinity in the absence of erythromycin but reduces affinity when erythromycin co-occupies the adjacent macrolide binding site; susceptibility testing in the absence of erythromycin therefore underestimates in vivo resistance. The D-zone test is not indicated because this mutation cannot be identified by disk diffusion.
ANSWER: B
Rationale:
The key discriminating pattern between these two isolates is the combination of erythromycin resistance with clindamycin susceptibility, which defines the phenotype requiring D-zone testing. The erm genes encoding 23S rRNA methyltransferases can be expressed in two patterns: constitutively, in which the gene is always active and produces high-level resistance to macrolides, lincosamides, and streptogramin B simultaneously (both erythromycin-R and clindamycin-R — matching the second isolate); or inducibly, in which the gene is normally suppressed and only activated in the presence of a macrolide inducer. With inducible expression, routine disk diffusion tests the organism without an inducer, yielding apparent clindamycin susceptibility. However, during clindamycin therapy in vivo, clindamycin itself — though a poor inducer compared to erythromycin — can nonetheless induce erm expression, converting the organism to high-level resistance and causing clinical treatment failure. The D-zone test detects inducible resistance by placing erythromycin and clindamycin disks in proximity: erythromycin induces erm expression in organisms near the clindamycin disk, flattening the inhibition zone into a D-shape. A positive D-zone test means clindamycin must be avoided despite apparent susceptibility.
Option A: Option A is incorrect because the premise of constitutive low-level erm expression producing clindamycin susceptibility in vitro but not in vivo is not the recognized mechanism; the inducible/constitutive distinction is binary in its clinical relevance, and the lincosamide nucleotidyltransferase mechanism described for the second isolate is not the standard explanation for constitutive MLSB resistance.
Option C: Option C is incorrect because the first isolate is erythromycin-resistant, which is inconsistent with a clindamycin-inactive efflux pump (mef) as the sole resistance mechanism; mef-mediated efflux typically produces macrolide resistance only (M phenotype) without affecting clindamycin, but the combination of ery-R plus clinda-S in the context of an oxacillin-resistant Staphylococcus requires D-zone testing for inducible erm, not automatic clearance for clindamycin use.
Option D: Option D is incorrect because both isolates do not have constitutive MLSB resistance; if the first isolate had constitutive erm expression, routine disk diffusion would detect clindamycin resistance, not susceptibility; constitutive resistance does not produce false-susceptible disk diffusion results.
Option E: Option E is incorrect because the mechanism described — a binding site mutation that modulates affinity depending on erythromycin co-occupancy — is a fabricated pharmacological concept that does not correspond to any recognized resistance mechanism for MLSB antibiotics.
10. A biochemist studying fosfomycin's molecular mechanism asks a resident to explain precisely how the drug inhibits MurA and why this inhibition is characterized as irreversible. Which of the following best describes the mechanism?
A) Fosfomycin acts as a competitive inhibitor of MurA by mimicking the structure of UDP-N-acetylglucosamine (UDP-GlcNAc), the substrate of the enzyme; by occupying the substrate binding pocket reversibly, it prevents substrate access and halts the first committed step of peptidoglycan synthesis without forming a covalent bond.
B) Fosfomycin is a time-dependent irreversible inhibitor that first binds reversibly to MurA's allosteric site, inducing a conformational change that then permanently occludes the active site; the initial reversible step is followed by slow covalent modification of an active-site lysine residue by the drug's epoxide moiety.
C) Fosfomycin inhibits MurA by chelating the divalent manganese ion (Mn²⁺) in the enzyme's active site, removing the cofactor essential for catalysis; because Mn²⁺ is irreplaceable in the active site under physiological conditions, the inhibition is effectively irreversible at clinical concentrations.
D) Fosfomycin is a phosphoenolpyruvate (PEP) analogue that covalently modifies the active-site cysteine residue of MurA via its reactive epoxide group; this covalent bond formation renders MurA permanently inactive, explaining why fosfomycin inhibition is irreversible and why the drug is effective at relatively low concentrations.
E) Fosfomycin inhibits MurA through a suicide inhibition mechanism in which the enzyme itself activates the drug via the same catalytic machinery used to process its natural substrate; the activated intermediate forms an irreversible covalent bond with the enzyme's active-site serine, permanently inactivating MurA.
ANSWER: D
Rationale:
Fosfomycin is a phosphoenolpyruvate (PEP) analogue — its three-carbon backbone and phosphonate group mimic the structure of PEP, the natural substrate for MurA. The drug binds to the active site of MurA and then reacts covalently with the active-site cysteine residue (Cys115 in Escherichia coli MurA) via its epoxide (oxirane) functional group. The epoxide undergoes nucleophilic ring-opening when attacked by the cysteine thiol, forming a stable thioether covalent adduct. This covalent modification is irreversible under physiological conditions, permanently inactivating the enzyme molecule. Because new MurA must be synthesized to restore peptidoglycan biosynthesis, the effective duration of fosfomycin's antibacterial action extends beyond the time the drug remains at measurable concentrations. This mechanism of action — a PEP analogue forming an irreversible covalent bond with an active-site cysteine — is structurally and mechanistically unique among all approved antibacterial classes, explaining why no cross-resistance exists with beta-lactams, glycopeptides, or other cell wall agents.
Option A: Option A is incorrect because fosfomycin is not a competitive reversible inhibitor that mimics UDP-GlcNAc; it is a PEP analogue that forms a covalent bond with the active-site cysteine, making the inhibition irreversible, not reversible.
Option B: Option B is incorrect because while fosfomycin does form a covalent bond with an active-site residue, it is not an allosteric inhibitor that induces conformational change before covalent modification; the modified residue is the active-site cysteine, not a lysine, and the mechanism described in Option B misrepresents the binding site and residue involved.
Option C: Option C is incorrect because fosfomycin does not inhibit MurA by chelating a divalent metal cofactor; MurA does not require a divalent metal for catalysis in the manner described, and metal chelation is not the mechanism of fosfomycin inhibition.
Option E: Option E is incorrect because while fosfomycin's mechanism does share conceptual features with suicide inhibition — the drug occupies the active site and reacts chemically — the modified residue is the cysteine, not a serine, and the enzyme does not catalytically activate the drug in the same way a true suicide substrate is processed; the mechanism is more precisely described as covalent active-site modification by the drug's inherent epoxide reactivity.
11. A 34-year-old woman with recurrent urinary tract infections presents with dysuria and urinary frequency. Urinalysis confirms a lower urinary tract infection. Before culture results return, the prescriber considers empiric nitrofurantoin. Which of the following most accurately describes the spectrum limitation of nitrofurantoin that is most relevant to empiric prescribing decisions for uncomplicated cystitis?
A) Nitrofurantoin lacks activity against Staphylococcus saprophyticus and Enterococcus faecalis, which are common causes of uncomplicated cystitis in young women; these two organisms account for approximately 30 percent of community-acquired cystitis cases, making nitrofurantoin unsuitable for empiric therapy.
B) Nitrofurantoin has activity against most Gram-negative uropathogens but lacks activity against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA), which are increasingly important causes of complicated urinary tract infections following urological procedures.
C) Nitrofurantoin has no reliable activity against Proteus mirabilis, Pseudomonas aeruginosa, or Klebsiella pneumoniae in most cases; while these organisms are less common causes of uncomplicated cystitis than Escherichia coli, urine culture results guide whether nitrofurantoin is appropriate once organism identity is confirmed.
D) Nitrofurantoin lacks activity against all Gram-positive organisms including Staphylococcus saprophyticus and enterococci, restricting its empiric use to infections where pure Gram-negative Enterobacteriaceae are overwhelmingly likely — primarily catheter-associated UTI where E. coli predominates exclusively.
E) Nitrofurantoin has no activity against Escherichia coli because the most prevalent E. coli uropathogens in community-acquired UTI have acquired complete nitroreductase deletion mutations, making nitrofurantoin ineffective for the most common pathogen in uncomplicated cystitis.
ANSWER: C
Rationale:
Nitrofurantoin's spectrum for urinary tract infections is somewhat narrower than many prescribers assume. While it has reliable activity against the most common uropathogens — Escherichia coli and Staphylococcus saprophyticus — it lacks reliable activity against Proteus mirabilis, Pseudomonas aeruginosa, and Klebsiella pneumoniae in most clinical isolates. The mechanism underlying this gap is complex: Proteus mirabilis, for example, may have reduced nitroreductase activity or altered membrane transport properties that limit drug accumulation. Pseudomonas aeruginosa and Klebsiella pneumoniae are generally considered intrinsically resistant or have low susceptibility rates in most clinical settings. This spectrum limitation is clinically relevant because these organisms do cause a minority of uncomplicated cystitis cases, and empiric nitrofurantoin will fail against them. However, urine culture results allow targeted selection: once E. coli susceptibility is confirmed, nitrofurantoin is appropriate; if Proteus, Pseudomonas, or Klebsiella are identified, an alternative must be chosen.
Option A: Option A is incorrect because nitrofurantoin does have activity against Staphylococcus saprophyticus and Enterococcus faecalis; these organisms are within nitrofurantoin's active spectrum; the claimed gap against these two organisms is inaccurate and would disqualify nitrofurantoin from being a guideline-supported empiric option for uncomplicated cystitis.
Option B: Option B is incorrect because nitrofurantoin does have activity against Staphylococcus aureus; the claim that MRSA represents a significant spectrum gap relevant to routine empiric nitrofurantoin prescribing for uncomplicated cystitis in a young woman overstates the clinical significance of this pathogen in this context.
Option D: Option D is incorrect because nitrofurantoin does have clinically relevant activity against Gram-positive uropathogens including S. saprophyticus and E. faecalis; restricting it to Gram-negative infections only misrepresents its spectrum.
Option E: Option E is incorrect because nitrofurantoin retains reliable activity against the large majority of community-acquired E. coli uropathogens; acquired nitroreductase deletion is not a prevalent resistance mechanism, and the claim that it has rendered nitrofurantoin ineffective against E. coli is not supported by current susceptibility data.
12. A 52-year-old woman has been taking nitrofurantoin 50 mg once daily as prophylaxis against recurrent urinary tract infections for the past three years. She presents with progressive exertional dyspnea, dry cough, and fatigue over six months. Chest CT shows bilateral ground-glass opacities and lower lobe interstitial thickening without pleural effusion. Pulmonary function testing reveals a restrictive pattern with reduced diffusing capacity. Nitrofurantoin is discontinued. Which of the following best describes the pulmonary toxicity syndrome in this patient and how it differs from the acute form?
A) This patient is experiencing chronic nitrofurantoin pulmonary toxicity — an insidious interstitial pneumonitis or pulmonary fibrosis that develops with prolonged use over months to years; unlike the acute form, which presents as an abrupt hypersensitivity pneumonitis within the first month of therapy with fever, eosinophilia, and rapid improvement after drug discontinuation, the chronic form progresses slowly, may not fully reverse even after stopping the drug, and requires monitoring with pulmonary function tests during long-term prophylactic use.
B) This patient has acute nitrofurantoin pulmonary toxicity that was unrecognized at the time of initial exposure; after three years of subclinical lung injury, the cumulative alveolar damage has now exceeded a threshold producing overt symptoms; the pathological process is identical to the acute form and will fully resolve within two to four weeks of drug discontinuation.
C) This patient is experiencing a drug-induced hypersensitivity reaction that is pharmacologically identical to acute nitrofurantoin pneumonitis; the only difference between acute and chronic forms is the total cumulative dose received, not the pathological mechanism; lung function returns to baseline in all patients within 90 days of stopping the drug.
D) The pulmonary findings in this patient are caused by nitrofurantoin-induced pulmonary vascular toxicity — the drug selectively injures pulmonary arteriolar endothelial cells, producing pulmonary arterial hypertension over time; unlike the parenchymal acute form, vascular injury is irreversible and the patient requires pulmonary vasodilator therapy in addition to drug discontinuation.
E) This patient has developed drug-induced organizing pneumonia (cryptogenic organizing pneumonia pattern) that is specific to nitrofurantoin's reactive intermediates accumulating in type II pneumocytes; the organizing pneumonia pattern is fully distinguishable from hypersensitivity pneumonitis on CT and responds completely to a short course of corticosteroids without requiring drug discontinuation.
ANSWER: A
Rationale:
Nitrofurantoin pulmonary toxicity occurs in two distinct clinical forms. The acute form presents within the first month of therapy — typically the first one to four weeks — as an abrupt hypersensitivity pneumonitis with fever, cough, dyspnea, peripheral eosinophilia, and bilateral pulmonary infiltrates. The acute form is immune-mediated, responds rapidly to drug discontinuation (often resolving within days to weeks), and eosinophilia supports the hypersensitivity mechanism. The chronic form, illustrated by this patient, develops insidiously over months to years of continuous use, particularly in patients on long-term prophylaxis. It presents as a progressive interstitial pneumonitis or pulmonary fibrosis with restrictive physiology and reduced diffusing capacity. Unlike the acute form, the chronic form may not fully reverse after drug discontinuation — some patients are left with persistent fibrosis and fixed functional impairment. Monitoring pulmonary function in patients on long-term nitrofurantoin prophylaxis is therefore clinically important. This distinction is directly relevant to how nitrofurantoin should be used: short treatment courses for acute cystitis carry very low pulmonary risk, while long-term prophylactic use demands monitoring and a low threshold for discontinuation if respiratory symptoms develop.
Option B: Option B is incorrect because the chronic form is not merely unrecognized acute toxicity reaching a cumulative threshold; it is a pathologically distinct syndrome (chronic interstitial fibrosis rather than acute hypersensitivity pneumonitis) that does not uniformly resolve rapidly after drug discontinuation.
Option C: Option C is incorrect because acute and chronic nitrofurantoin pulmonary toxicity are not pharmacologically identical; they differ in mechanism (immune-mediated hypersensitivity versus chronic toxic fibrosis), clinical presentation, onset time, and prognosis; not all patients recover to baseline lung function after chronic toxicity.
Option D: Option D is incorrect because nitrofurantoin pulmonary toxicity does not characteristically cause pulmonary arterial hypertension through selective arteriolar endothelial injury; the toxicity involves the lung parenchyma (alveoli, interstitium), not the pulmonary vasculature, and pulmonary vasodilator therapy is not the treatment.
Option E: Option E is incorrect because organizing pneumonia is not the recognized specific pattern of nitrofurantoin chronic pulmonary toxicity; the established syndromes are acute hypersensitivity pneumonitis and chronic interstitial fibrosis; furthermore, drug discontinuation is mandatory, not optional, and corticosteroids alone without stopping the offending drug would be inappropriate management.
13. A pharmacology student asks why sulfamethoxazole (SMX) inhibits bacterial folate synthesis but does not inhibit human folate synthesis, given that both bacteria and humans require tetrahydrofolate. Which of the following best explains the basis for this selectivity?
A) SMX inhibits dihydrofolate reductase (DHFR) with much higher affinity in bacteria than in humans because the bacterial enzyme has a structurally distinct active site that accommodates the sulfonamide scaffold; human DHFR has a different binding geometry that prevents SMX from occupying the active site at clinical concentrations.
B) SMX is selectively toxic to bacteria because it is actively transported into bacterial cells by a bacterial-specific folate uptake transporter that concentrates the drug intracellularly to inhibitory levels; human cells lack this transporter and therefore do not accumulate SMX to concentrations sufficient for DHFR inhibition.
C) SMX inhibits dihydropteroate synthase (DHPS) in both bacteria and humans equally, but human cells have a high-capacity alternative pathway for tetrahydrofolate synthesis that bypasses DHPS; bacteria lack this alternative pathway and are therefore selectively dependent on the DHPS-catalyzed step.
D) SMX selectively inhibits bacterial DHPS by chelating the magnesium cofactor required for bacterial DHPS catalysis; human DHPS uses a zinc cofactor with a different coordination geometry that SMX cannot chelate, providing absolute selectivity for the bacterial enzyme.
E) SMX is a structural analogue of para-aminobenzoic acid (PABA) that competitively inhibits dihydropteroate synthase (DHPS); bacteria must synthesize folate de novo and cannot import preformed folate from their environment, making them entirely dependent on DHPS; human cells lack DHPS entirely because they cannot synthesize folate and must obtain it as a preformed vitamin from dietary sources, meaning SMX has no mammalian target to inhibit.
ANSWER: E
Rationale:
The basis of sulfamethoxazole's selective toxicity is one of the most elegant examples of exploiting a fundamental biochemical difference between bacteria and humans. SMX is a structural analogue of para-aminobenzoic acid (PABA), mimicking the substrate that dihydropteroate synthase (DHPS) uses to synthesize dihydropteroic acid — the immediate precursor in the de novo folate synthesis pathway. Bacteria are auxotrophic for folate synthesis: they cannot import preformed folate from their environment (lacking the transport mechanisms required for uptake of the intact folate molecule) and must synthesize it entirely through the DHPS-catalyzed pathway. Therefore, DHPS inhibition is lethal to bacteria. Human cells, by contrast, have entirely lost the DHPS gene over the course of evolution — humans are completely dependent on dietary preformed folate (as folic acid or 5-methyltetrahydrofolate), which is imported by folate transport proteins. Because human cells do not possess DHPS at all, there is simply no mammalian target for SMX to inhibit. This complete absence of the target enzyme — not reduced affinity, not alternative pathways, not transport differences — is the explanation for SMX's selective toxicity.
Option A: Option A is incorrect because SMX does not inhibit DHFR; SMX's target is DHPS; the DHFR inhibitor in TMP-SMX is trimethoprim, not sulfamethoxazole.
Option B: Option B is incorrect because SMX's selectivity is based on the complete absence of the target enzyme in human cells, not on differential drug uptake via a bacterial transporter.
Option C: Option C is incorrect because humans do not possess DHPS and therefore have no alternative pathway that bypasses it; the premise of an alternative human pathway is inaccurate.
Option D: Option D is incorrect because DHPS selectivity is not based on metal cofactor differences between bacterial and human enzymes; the human genome does not encode DHPS at all, making metal cofactor comparisons irrelevant.
14. A 68-year-old man with chronic obstructive pulmonary disease (COPD) and bronchiectasis has been on chronic immunosuppressive therapy following a lung transplant. He develops a pulmonary infection and bronchoalveolar lavage culture grows Stenotrophomonas maltophilia. The infectious diseases consultant recommends TMP-SMX as the primary treatment. Which of the following best explains why TMP-SMX is the preferred agent for this organism, and what intrinsic resistance property of Stenotrophomonas makes most other commonly used antibiotics ineffective?
A) TMP-SMX is preferred for Stenotrophomonas maltophilia because it is the only antibiotic class with activity against organisms that produce metallo-beta-lactamases (MBLs); Stenotrophomonas produces an MBL (L1) that inactivates all carbapenem, penicillin, and cephalosporin antibiotics, and TMP-SMX acts on the folate pathway, which is completely unaffected by beta-lactamase activity.
B) TMP-SMX is the established first-line treatment for Stenotrophomonas maltophilia infections; Stenotrophomonas is intrinsically resistant to carbapenems due to chromosomally encoded metallo-beta-lactamase (L1) and serine-beta-lactamase (L2) production, resistant to aminoglycosides via multiple efflux pumps, and resistant to many fluoroquinolones; TMP-SMX exploits the organism's dependence on de novo folate synthesis and achieves reliable bactericidal activity with acceptable tolerability.
C) TMP-SMX is preferred for Stenotrophomonas maltophilia exclusively because this organism is the only Gram-negative bacterium known to require exogenous folate supplementation for growth, making it paradoxically more susceptible to folate pathway inhibition than other Gram-negative species that can synthesize folate independently.
D) TMP-SMX is used for Stenotrophomonas maltophilia as a last resort because all other antibiotics including carbapenems, anti-pseudomonal penicillins, and aminoglycosides retain good activity against this organism; TMP-SMX is recommended only when these preferred options are contraindicated due to allergy or renal impairment.
E) TMP-SMX is preferred for Stenotrophomonas maltophilia because this organism is uniquely susceptible to the sulfonamide component (SMX) alone and trimethoprim adds no incremental activity; the combination ratio can therefore be adjusted to use a higher SMX proportion to maximize activity against this specific pathogen.
ANSWER: B
Rationale:
Stenotrophomonas maltophilia is an intrinsically multidrug-resistant Gram-negative bacillus that poses a significant therapeutic challenge in immunocompromised patients, chronic lung disease patients, and individuals who have received broad-spectrum antibiotic therapy or have indwelling devices. Its intrinsic resistance profile is defined by several mechanisms: chromosomally encoded class B metallo-beta-lactamase (L1) that inactivates all carbapenem antibiotics (including meropenem and imipenem, which are active against Pseudomonas and many other Gram-negatives), chromosomally encoded class A serine-beta-lactamase (L2) that inactivates cephalosporins and penicillins, constitutively expressed efflux pumps (SmeDEF and others) that export aminoglycosides and fluoroquinolones, and intrinsic outer membrane impermeability to many other drug classes. This combination makes most available antibiotics unreliable. TMP-SMX remains the primary treatment option because Stenotrophomonas retains dependence on de novo folate synthesis, the folate pathway is fully intact and susceptible, and TMP-SMX achieves the sequential folate pathway inhibition at both DHPS (SMX) and DHFR (TMP) that produces adequate bactericidal activity. Alternative options when TMP-SMX is contraindicated include ticarcillin-clavulanate, minocycline, and levofloxacin in some settings.
Option A: Option A is incorrect because while TMP-SMX's activity against Stenotrophomonas is related to the organism's resistance to beta-lactams via MBL production, TMP-SMX is not the only antibiotic class active against MBL producers; additionally, the claim that TMP-SMX is the sole effective drug due exclusively to MBL production overly simplifies the organism's complex resistance profile.
Option C: Option C is incorrect because Stenotrophomonas does not require exogenous folate supplementation; like other bacteria, it synthesizes folate de novo and is therefore susceptible to DHPS inhibition by SMX; the premise that it is uniquely dependent on exogenous folate is inaccurate.
Option D: Option D is incorrect because carbapenems, anti-pseudomonal penicillins, and aminoglycosides do not retain reliable activity against Stenotrophomonas maltophilia; the organism's intrinsic MBL production eliminates carbapenem activity, and aminoglycoside efflux is well-characterized; TMP-SMX is the first-line choice, not a last resort.
Option E: Option E is incorrect because trimethoprim's contribution to anti-Stenotrophomonas activity is not negligible; the sequential folate blockade from both components produces synergistic inhibition, and the fixed 1:5 ratio of TMP:SMX is established pharmacologically; adjusting the ratio to maximize the SMX proportion is not current practice.
15. A 44-year-old man with HIV is started on high-dose TMP-SMX for Pneumocystis jirovecii pneumonia (PCP) treatment. On day four of therapy, his serum creatinine rises from 0.9 mg/dL to 1.6 mg/dL. He has no symptoms of acute kidney injury, urine output is unchanged, and his cystatin C level is normal. Which of the following best explains this laboratory finding?
A) The creatinine rise represents true acute tubular necrosis caused by direct nephrotoxic effects of the sulfamethoxazole component on proximal tubular cells; the normal cystatin C value is unreliable in the context of HIV infection because chronic inflammation independently suppresses cystatin C production.
B) The creatinine rise represents immune complex-mediated glomerulonephritis triggered by TMP-SMX acting as a hapten; the normal cystatin C confirms that glomerular filtration is preserved in the early phase, but progression to frank nephritis with proteinuria and hematuria is expected within two to three weeks if the drug is not discontinued.
C) The creatinine rise represents trimethoprim-induced tubular secretion blockade of potassium leading to hyperkalemia-mediated vasoconstriction of the afferent arteriole; the resulting reduction in renal blood flow causes both the creatinine rise and the normal cystatin C because cystatin C is not sensitive to hemodynamic reductions in GFR below 30 percent.
D) Trimethoprim competes with creatinine for secretion by organic anion transporters (OATs) in the proximal tubule, reducing tubular creatinine secretion and raising serum creatinine without any reduction in true glomerular filtration rate (GFR); cystatin C, which is cleared solely by glomerular filtration independent of tubular secretion, remains normal, confirming that actual kidney function is preserved.
E) The creatinine rise represents sulfonamide-induced crystalluria with tubular obstruction; sulfamethoxazole crystals precipitate in the proximal tubular lumen at high urine concentrations, physically blocking tubular flow and causing a post-renal type of serum creatinine elevation; the normal cystatin C reflects preservation of glomerular function upstream of the tubular obstruction.
ANSWER: D
Rationale:
Trimethoprim is a well-characterized inhibitor of organic cation and anion transporters (particularly OCT2 and OAT family members) in the proximal tubule that are responsible for the active secretion of creatinine from blood into the tubular lumen. Under normal conditions, approximately 10 to 15 percent of creatinine excretion is attributable to tubular secretion, with the remainder cleared by glomerular filtration. When trimethoprim competitively inhibits this secretion, creatinine accumulates in the bloodstream — raising serum creatinine — without any actual reduction in glomerular filtration. This is a pharmacological interference with creatinine handling, not kidney injury. The normal cystatin C provides the critical confirmatory evidence: cystatin C is freely filtered at the glomerulus and reabsorbed and catabolized by proximal tubular cells without any secretion component, making it entirely independent of tubular creatinine secretion. A normal cystatin C in the setting of a rising creatinine is strong evidence that the creatinine rise reflects tubular secretion blockade, not reduced GFR. This distinction is clinically important: the creatinine elevation does not require dose reduction or drug discontinuation on nephrotoxicity grounds, though the true GFR should be assessed by cystatin C-based equations when dosing decisions for other renally cleared drugs are made.
Option A: Option A is incorrect because the normal cystatin C is not unreliable in HIV infection due to inflammation; the cystatin C in this context is the key discriminator between true GFR reduction and pseudocreatininemia from tubular secretion blockade, and acute tubular necrosis would produce both creatinine and cystatin C elevation.
Option B: Option B is incorrect because TMP-SMX-induced glomerulonephritis via hapten formation is not a recognized clinical entity in the manner described, and the interpretation of normal cystatin C as an early-phase finding before progression to frank nephritis misrepresents the pharmacological explanation for this specific clinical pattern.
Option C: Option C is incorrect because trimethoprim-induced hyperkalemia works via ENaC blockade in the collecting duct, not potassium-mediated afferent arteriolar vasoconstriction; this mechanism does not explain the creatinine elevation, and cystatin C is sensitive to hemodynamic GFR reductions.
Option E: Option E is incorrect because while sulfonamide crystalluria is a recognized adverse effect at high doses with inadequate hydration, it would produce a different clinical picture — typically hematuria and flank pain — and would not explain a smooth isolated creatinine rise with a normal cystatin C in the context of high-dose TMP-SMX.
16. An ICU pharmacist briefs the medical team on the dosing and formulation of intravenous colistin being initiated for a patient with carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia. She explains that the drug is administered as a prodrug. Which of the following most accurately describes the prodrug relationship and its clinical implications for dosing?
A) Colistin is administered intravenously as polymyxin B sulfate, which is the inactive prodrug; polymyxin B is converted by plasma esterases to colistin (polymyxin E) in the circulation over approximately 6 to 8 hours, necessitating a loading dose strategy to achieve early therapeutic colistin concentrations.
B) Colistin is administered as a liposomal encapsulated prodrug formulation that is activated only after phagocytic uptake into alveolar macrophages, where lysosomal phospholipases cleave the lipid bilayer and release active colistin directly at the site of pulmonary infection; systemic colistin concentrations therefore do not reflect the pharmacologically active concentration at the lung.
C) Colistin is administered intravenously as colistimethate sodium (CMS), an inactive sulfomethylated prodrug; CMS is converted to active colistin by non-enzymatic hydrolysis in vivo, but this conversion is slow and incomplete, so plasma contains a mixture of CMS and colistin at any time; dosing is calculated in terms of colistin base activity (CBA) to ensure consistent dosing across different formulations that may express potency in IU or milligrams.
D) Colistin is administered in its fully active form as colistin sulfate intravenously; the term "prodrug" applied to colistin refers only to the oral formulation (colistimethate sodium), which requires enteric conversion to active colistin; parenteral colistin sulfate requires no activation and achieves immediate bactericidal concentrations.
E) Colistin is administered as an N-acyl prodrug that is activated by bacterial cell wall phosphatases at the site of infection; because activation requires contact with viable bacteria, colistin selectively accumulates in infected tissues, minimizing systemic nephrotoxicity that would otherwise occur if the active drug circulated freely in plasma.
ANSWER: C
Rationale:
Colistin is formulated for intravenous use as colistimethate sodium (CMS), also called colistin methanesulfonate or sodium colistimethanesulfonate. CMS is a chemically modified, inactive prodrug in which the free amino groups of colistin's cyclic peptide are sulfomethylated, substantially reducing its toxicity and making it suitable for parenteral administration. After IV administration, CMS undergoes non-enzymatic hydrolysis in plasma and tissue to release active colistin. This conversion is slow — peak colistin concentrations are not achieved immediately — and incomplete, meaning that at any given time, plasma contains a mixture of the prodrug (CMS) and the active drug (colistin). Several clinical implications follow from this pharmacology: first, a loading dose is recommended to achieve therapeutic colistin concentrations more rapidly than would occur with maintenance dosing alone; second, dosing is expressed in terms of colistin base activity (CBA) because different commercial preparations express potency in international units (IU), milligrams of colistin base, or milligrams of CMS, and these are not interchangeable without conversion; prescribing errors in colistin dosing are a recognized patient safety problem stemming from this formulation complexity.
Option A: Option A is incorrect because polymyxin B sulfate is a separate, distinct drug — not a prodrug of colistin; polymyxin B is administered directly in its active form without prodrug conversion, whereas colistin (polymyxin E) is the agent administered as CMS; the two are distinct compounds with different structures and dosing.
Option B: Option B is incorrect because IV colistin is not a liposomal formulation activated by phagocytic uptake; liposomal colistin preparations are investigational or inhaled formulations for specific indications, and the described mechanism of macrophage-selective activation does not describe standard IV CMS pharmacology.
Option D: Option D is incorrect because colistin sulfate is the oral formulation used for gut decontamination, not the parenteral formulation; the standard intravenous formulation is CMS (colistimethate sodium), which is the prodrug, not active colistin sulfate; the statement reverses the clinical roles of these two formulations.
Option E: Option E is incorrect because CMS activation does not require bacterial cell wall phosphatases; the hydrolysis from CMS to active colistin is a non-enzymatic chemical reaction that occurs spontaneously in plasma and tissues regardless of the presence of bacteria.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.